Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
200 Leser
Artikel bewerten:
(1)

Ligases Enzyme Market Revenue to Surpass USD 631 Million by 2030, Says P&S Intelligence

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The ligases enzyme market revenue will be $631.7 million by 2030, growing from $367.4 million in 2021 at a 6.2% CAGR. This is attributed to the growing usage of these chemicals in the detection of infectious diseases and genetic abnormalities, along with the booming cancer burden.

P&S Intelligence (PRNewsfoto/P&S Intelligence)

North America Generates Highest Revenue, Led by U.S.

  • The highest revenue in the market, of $224.7 million, was generated in North America last year. The extensive R&D activities in disease diagnostics and treatment using these enzymes will allow the region to keep dominating the market over this decade.
  • A hub for biotechnology, the region is witnessing an increasing usage of these agents in protein engineering, PCR, cloning, mutation detection, drug target, and NGS.
  • The U.S. holds the larger share in the ligases enzyme market of North America, due to the high incidence of genetic defects and a rise in the number of people needing long-term care. Additionally, the government efforts aimed at the utilization of ligases enzymes in molecular diagnosis tools drives the country's market.

Get the sample pages of this report: https://www.psmarketresearch.com/market-analysis/ligases-enzyme-market-size/report-sample

T4 DNA ligases, the largest category, will witness a 6.8% CAGR, the highest within the product segment. T4 DNA is used for the effective and quick ligation of blunt double-stranded as well as cohesive-ended DNA fragments during molecular diagnoses; it is also used for T/A cloning.

Considered a highly flexible ligase, T4 DNA is the popular choice in the majority of traditional molecular cloning procedures. T4 DNA offers effective ligation in high temperatures and media with high salt concentrations. Additionally, this biological agent achieves ligation in merely 5 minutes at room temperature, with the use of a specialty optimized buffer.

As a source for these agents, Escherichia coli generates almost 35% of the ligases enzyme market revenue, as DNA ligases obtained from this bacterium were the first to be extracted and analyzed. Additionally, the presence of its own ligase allows E. coli to join the ends of recombinant DNA in a cell. As a result, DNA ligase from E. coli is used to join two fragments of recombinant DNA, before the complete DNA is embedded into a cell.

The largest category within the application segment, molecular cloning will have a size of $134.8 million in 2030. This method is used to create recombinant DNA and replicate them inside cells. As a result, molecular cloning is used to clone stem cells, to treat a variety of diseases, and to obtain a better understanding of genetic conditions.

Browse detailed report on Ligases Enzyme Market Size, Share and Demand Forecast to 2030

With revenue of $135.5 million, research laboratories and institutions lead the ligases enzyme market on the basis of end user. This is attributed to the role of these institutions in biotechnology research, which brings about innovations in the domain of genetic testing. Moreover, research labs are extensively working to discover the biological and chemical modulators of ligases enzyme targets with regulatory approval.

Ligases Enzyme Market Report Coverage

By Product

  • Quick Ligase
  • T4 DNA Ligase
  • E. Coli DNA Ligase
  • Tth DNA Ligase
  • T4 RNA Ligase
  • Pfu DNA Ligase

By Source

  • Archaebacterium
  • Escherichia coli
  • Thermus thermophilus
  • Pyrococcus furiosus

By Application

  • Ligase Chain Reaction
  • Ligase Detection Reaction
  • Next-Generation Sequencing
  • Repeat Expansion Detection
  • Rolling Circle Amplification
  • Proximity Ligation Assay
  • Molecular Cloning
  • Ligation Mediated PCR
  • Mutation Detection

By End User

  • Research Laboratories and Institutions
  • Pharmaceutical and Biopharmaceutical Companies
  • Diagnostic Laboratories

Regional Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
  • Latin America
    • Brazil
    • Columbia
    • Chile
  • Middle East and Africa
    • Saudi Arabia
    • South Africas

Browse More Reports Published by P&S

Global DNA Extraction Kit Market Size, Share and Demand Forecast to 2030

Global Microarray Analysis Market Size, Share and Demand Forecast to 2030

Global Epigenetics Market Size, Share and Demand Forecast to 2030

About P&S Intelligence

P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies.

Contact:

Prajneesh Kumar
P&S Intelligence
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Follow Us: LinkedIn Twitter

Logo - https://mma.prnewswire.com/media/1224988/P_and_S_Intelligence_Logo.jpg

© 2022 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.